8-K: Profound Medical's TULSA Procedure Shows Superior Post-Operative Outcomes Compared to Robotic Prostatectomy in CAPTAIN Trial

Profound Medical's TULSA procedure demonstrates statistically significant improvements in post-operative experience compared to robotic radical prostatectomy in the CAPTAIN trial.

Summary

• Profound Medical Corp. announced initial perioperative data from the CAPTAIN trial, a Level 1 study comparing the TULSA procedure with robotic radical prostatectomy (RP) for intermediate-risk prostate cancer.
• The study, which began in 2022, recruited patients from 20 sites in the US, two in Canada, and one in Europe.
• As of January 2025, 201 patients were randomized, with 194 treated or scheduled for treatment (69% TULSA, 31% RP).
• The TULSA procedure showed statistically significant improvements in blood loss (0 mL vs. 100 mL for RP), length of stay (0.29 days vs. 1.24 days for RP), and post-operative pain.
• TULSA patients also reported significantly higher overall health and fewer problems with mobility, self-care, and usual activities in the first month post-treatment.

Sentiment

Score: 8

Explanation: The document presents positive results from a clinical trial, suggesting a promising alternative treatment for prostate cancer. The tone is optimistic and highlights the benefits of the TULSA procedure.

Positives

• TULSA procedure results in zero blood loss compared to 100 mL median blood loss for robotic prostatectomy.
• Patients undergoing TULSA had a significantly shorter hospital stay (0.29 days) compared to robotic prostatectomy (1.24 days).
• TULSA patients experienced less post-operative pain compared to those undergoing robotic prostatectomy.
• TULSA patients reported better overall health and fewer limitations in mobility, self-care, and daily activities post-treatment.

Risks

• The long-term efficacy of TULSA compared to RP is still being evaluated, with the primary efficacy endpoint measured at three years.
• The study is ongoing, and further data is needed to confirm these initial findings.
• Reimbursement policies by insurance companies may be influenced by the complete CAPTAIN trial results.

Future Outlook

Profound Medical plans to continue reporting CAPTAIN follow-up data and expand the clinical evidence for TULSA across the prostate disease spectrum.

Management Comments

• Dr. Meng commended the study investigators for conducting the CAPTAIN trial, highlighting TULSA's proven safety and efficacy.
• Arun Menawat, Profound's CEO, stated that the CAPTAIN perioperative outcomes are important for patient demand and insurance coverage policies.

Industry Context

The announcement positions TULSA as a potential alternative to robotic prostatectomy, a common treatment for localized prostate cancer, with the potential for improved patient outcomes and reduced healthcare costs.

Comparison to Industry Standards

• The CAPTAIN trial is a Level 1 randomized controlled trial, considered the gold standard for evidence-based research, comparing TULSA to robotic prostatectomy.
• Robotic prostatectomy is a widely adopted surgical technique for prostate cancer treatment, with established recovery times and complication rates.
• The TULSA procedure aims to offer a less invasive alternative with potentially faster recovery and fewer side effects compared to robotic prostatectomy.

Stakeholder Impact

• Shareholders may react positively to the promising clinical trial results.
• Patients may benefit from a less invasive treatment option with faster recovery.
• Insurance companies may consider the CAPTAIN trial results when making coverage policies.

Next Steps

• Continue reporting CAPTAIN follow-up data.
• Expand clinical evidence for TULSA across the prostate disease spectrum.

Key Dates

Keywords

TULSA, prostate cancer, robotic prostatectomy, CAPTAIN trial, Profound Medical, MRI-guided, ablation, perioperative data